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Abstract 
Few studies on adult pneumococcal septic arthritis are sufficiently large enough to assess 
both epidemiological trends following routine pneumococcal immunization and clinical 
disease. With major shifts in serotypes causing invasive pneumococcal disease (IPD), we 
wanted to determine the clinical phenotype of adult septic arthritis caused by Streptococcus 
pneumoniae. We conducted a retrospective cohort study of pneumococcal infections in 
Bristol and Bath, UK, 2006-2018. We defined pneumococcal septic arthritis as adults with 
clinically-confirmed septic arthritis, with pneumococcus isolated from sterile-site culture or 
urinary antigen test positivity. Clinical records were reviewed for each patient in the cohort. 
Septic arthritis accounted for 1.7% of all IPD cases. 45 cases of adult pneumococcal septic 
arthritis occurred, with disease typically affecting older adults and those with underlying 
comorbidity. 67% patients had another focus of infection during their illness. 66% patients 
required increased care on discharge and 43% had reduced range of movement. In-hospital 
case fatality rate was 6.7%. One-year patient mortality was 31%.  
Currently most cases of adult pneumococcal septic arthritis are due to non-PCV13 serotypes 
which are associated with more severe disease. PCV13 serotypes had higher prevalence of 
concomitant pneumococcal infection at another site (36.6% versus 73.7%), increased 
 
 
intensive care or high-dependency unit requirement (0% versus 32.4%), and higher inpatient 
and 1-year case fatality rate (0% versus 8.8%, and 27.3% versus 32.4% respectively) 
compared to non-PCV13 serotypes.  
Pneumococcal septic arthritis remains a small proportion of IPD. However, there is 
significant associated morbidity and mortality, and pneumococcal septic arthritis requires 
monitoring in coming years.   
 




The annual incidence of septic arthritis in adults in Western Europe ranges between 
4–10 per 100,000 patient-years and appears to be increasing [1,2]. Septic arthritis is 
associated with significant morbidity and long-term disability, with case fatality rates (CFR) 
up to 15% [1,3,4]. Accurate and timely diagnosis is critical for preventing irreversible joint 
destruction, ankylosis and avascular necrosis [5,6]. Infection can spread locally, damaging 
bones and nerves, and potentially cause systemic sepsis [6]. Treatment involves empirical 
antibiotic therapy and removal of the infection source.  
Staphylococcus aureus is the commonest cause of septic arthritis, causing 30-50% 
cases. Streptococcus pneumoniae is a recognised but rare cause of septic arthritis, causing 2-
4% cases, with a higher prevalence in some cohorts [7,8]. Over 100 pneumococcal serotypes 
are recognised, with the unique capsular polysaccharide of certain serotypes being the 
antigenic targets in current vaccines. Two vaccines are currently used in the UK. The 23-
 
 
valent pneumococcal polysaccharide vaccine (PPV23) has been available for over three 
decades and is indicated for at-risk patients aged ≥2 years and all adults aged ≥65 years 
[9,10]. The UK implemented the 7-valent pneumococcal conjugate vaccine (PCV7) into the 
national infant immunisation programme in September 2006 [11].  In April 2010, this vaccine 
was replaced with 13-valent PCV (PCV13) [12]. Both conjugate vaccines have been 
associated with large declines in vaccine-serotype invasive pneumococcal disease (IPD) 
across all age groups [11,12], because of direct and indirect (herd) protection. However, 
increases in IPD due to non-vaccine serotypes (serotype replacement disease) have been 
reported in the UK [13,14] and other countries [15-18]. In older adults in the UK, serotype 
replacement disease has nearly cancelled-out the reduction in vaccine-serotype IPD [13]. 
Consequently, there have been major shifts in pneumococcal serotypes causing IPD, 
especially in adults and elderly patients, without significant reduction in disease burden.  
So far, there have been very few studies on pneumococcal septic arthritis in adults 
because it is so uncommon. Most studies are too small to assess epidemiological trends 
following PCV implementation (especially PCV13) or describe clinical characteristics and 
outcomes of adult patients with septic arthritis due to different serotypes. Therefore, we 
aimed to describe the epidemiology, serotype distribution, clinical characteristics, risk factors 
and outcomes of pneumococcal septic arthritis in adults in Bristol and Bath, UK, since PCV7 
introduction into the childhood immunisation programme in England and eight years after its 
replacement with PCV13 in 2010. 
 




This study involved adults aged ≥16 years admitted to the three hospitals providing 
emergency care in Bristol and Bath (University Hospitals Bristol and Weston NHS Trust, 
North Bristol NHS Trust and The Royal United Hospital) between January 2006 and 
December 2018. The hospitals and populations are described in Supplementary data 1. 
 
Case definitions 
Cases were identified retrospectively by searching the Laboratory Information 
Management System (LIMS) database (Clinisys WinPath Enterprise). S. pneumoniae was 
confirmed on culture of blood or fluid from affected joint(s) at a central laboratory, using 
standard microbiological techniques outlines in UK standards for microbiology investigations 
(UK-SMI) combined with API®-20 Strep (BioMérieux, UK) and/or MALDI-TOF (matrix-
assisted laser desorption/ionisation/time of flight) mass spectrometer (Bruker, UK). 
Confirmed cases were linked with the Public Health England (PHE) national reference 
laboratory to obtain serotype data for each case [19]. Serotyping was performed by 
phenotypic methods including the Quellung reaction until September 2017, which was 
replaced by whole genome sequencing thereafter [20]. A positive UAT (BinaxNOW®, Alere, 
UK) was also considered confirmative of pneumococcal infection. Confirmation of 
pneumococcal infection in addition to a diagnosis of septic arthritis by the treating physician 
was considered diagnostic of pneumococcal septic arthritis.  
S. pneumoniae serotypes contained within each vaccination are listed in 





Detailed clinical records were obtained from each hospital and were reviewed for the 
following data: age, gender, smoking status, co-morbidities, concomitant pneumococcal 
infection, joint(s) affected, treatment including surgical management, and clinical outcomes. 
Laboratory findings were examined in addition to clinical observations on presentation of the 
septic arthritis episode.  
 
Data Analysis and Statistics 
Data were analyzed using SPSS, version 25.0 (New York, IBM). Incidence rates were 
calculated by dividing number of cases by the adult population within the catchment area of 
the three hospitals. Categorical variables are presented as counts and percentiles. Continuous 
data were tested for normality using the Shapiro-Wilk Test, with P<0.05 considered 
significant: normally distributed data are presented as means and standard deviations (SD), 
whilst data that did not follow a normal distribution are presented as medians with 
interquartile ranges (IQR). Non-parametric data were analyzed using appropriate statistical 
tests including the two-sided Chi-squared test.  
 
Ethics Approval 
The study was approved by the Health Research Authority, UK (IRAS 265437).  
Results 
Patient Cohort and Epidemiology 
We identified 2657 clinical episodes of IPD between January 2006 and December 
2018: 45 (1.7%) had septic arthritis (Table 1). The median age of patients with septic arthritis 
 
 
was 68 years (IQR 56-78, range 34-92). IPD requiring hospitalisation increased throughout 
the study period (Figure 1A) and incidence of pneumococcal septic arthritis requiring 
hospitalisation also increased (Figure 1B). Annual blood and joint cultures increased by 38% 
and 23% respectively from 2006 to 2018, with the increase in testing less than the increase in 
pneumococcal septic arthritis detected in hospitalised patients.   
 
Clinical Characteristics 
Typical presentation of pneumococcal septic arthritis was sudden onset joint pain with 
a swollen, hot joint and associated fever (≥38°C). Tachycardia occurred in 44% patients, but 
hypotension was uncommon. Symptoms were present for median 3 days (IQR1-4, range 0-5) 
before diagnosis for those who survived, and 4 days (IQR2-5, range 2-5) in non-surviving 
patients (Table 1).  
Thirty patients (67%) had pneumococcal infection at a second site, including 
pneumonia in 26 (86% of second site cases) (with one case complicated by empyema); two 
cases (7% second site cases) of meningitis and one of pneumonia and meningitis; and one 
case of mycotic aortic aneurysm. For most (93%) patients in this study, the admitting 
physician considered septic arthritis the primary infection focus. Most patients (82%) had 
monoarticular septic arthritis: the knee was the most common joint involved (23 joints, 51%), 
followed by the shoulder (11 joints, 24%). There were five prosthetic joint infections: four 
knee and one hip infection.  
 
Underlying Disease(s)/Risk factors 
 
 
Most patients (96%) had more than one co-morbidity or risk factor (including 
recreational drug use, joint trauma, severe malnutrition) predisposing them to disease. One 
patient was pregnant, sustained trauma to the affected joint and subsequently underwent early 
Caesarean section in the third trimester with good outcome. Medical co-morbidities occurring 
frequently included hypertension (n=14), diabetes mellitus (n=9), chronic renal failure (n=4), 
left ventricular failure (n=5) (Table 1).  
Pre-existing malignancies included renal cell carcinoma (2); malignant melanoma (2); 
colon (1), oesophageal (1), and breast cancer (1). Two patients were diagnosed with multiple 
myeloma during admission for pneumococcal septic arthritis. Pre-existing joint disease was 
documented in 19 patients, including osteoarthritis and rheumatoid arthritis. Smoking, 
alcohol misuse and injecting drug use (IDU) was reported in 24, 5 and 2 patients, 
respectively.  
29 patients were aged ≥65 years, and a further 7 deemed eligible for PPV23 
vaccination under current UK guidelines [9]; 20 of these individuals had received PPV23 
vaccination prior to their pneumococcal septic arthritis.  
 
Outcome 
The median length of hospital admission was 25 days (IQR 16-30, range 7-62) with 
two non-survivors dying <72 hours from admission and 25 survivors discharged home. 10 
patients transferred to a rehabilitation/specialist centre. Almost half of survivors (47%) 
required additional care on discharge (Table 2).  
Three (7%) patients died during hospital admission: all had severe comorbidities. One 





/L at presentation. The second had a history of alcohol misuse, malnutrition 
and sustained significant joint trauma; the third patient had malignant melanoma, ischaemic 
heart disease, cerebrovascular disease and dementia. All these patients had a lymphocyte 
count<1.0×10
9
/L on admission (although eleven other patients with lymphopenia survived). 
Two of these patients had polyarticular infection with concomitant pneumonia; all had 
infection with a PPV23 serotype not in PCV13 (PPV23nonPCV13) (8, 12F and 33F). Patients 
with cancer had poor survival with four fatalities within 1 year of presentation (CFR 44%): 
two died during hospital admission and two after discharge.  
Ten additional patients died within one year of presentation (overall one-year fatality, 
31%). Six patients succumbed to respiratory infection, with no causative pathogens 
identified. Of the 31 patients surviving over a year, 28 had follow-up records detailing 
recovery: 15 recovered joint function, and 13 had reduced range of movement (ROM). Three 
patients with osteoarthritis recovered baseline joint function. All patients with complicated 
pneumococcal infection (empyema, meningitis or mycotic aneurysm) had long-term reduced 
ROM or died.  
 
Investigation Findings 
Initial investigation results are summarised in Table 1. 37 patients had leucocytosis (defined 
as WBC >11.0×10
9
/L) and 42 had neutrophilia (defined as neutrophils >7.7x10
9
/ L). One 
patient had leukopaenia (defined as WBC <3.0×10
9
/L) and 14 patients had lymphopenia 
(defined as lymphocytes <1.5x10
9
/L). C-reactive protein was >300mg/L in 12 patients (one 
of whom died), between 200-300mg/L in 14 patients (two of whom died) and 100-200mg/L 
in 19 patients. Most patients were hypoalbuminaemic: 26 patients (57%) had albumin ≤30g/L 
(normal range 35-50g/L).  
 
 
All patients had joint cultures taken: 43 (96%) were positive for pneumococcus. Both 
patients with negative joint cultures had fluid obtained >24 hours after antibiotic 
commencement. 13 (29%) patients were diagnosed through positive joint culture alone. 
Blood cultures were positive in 28 patients, while 8 had a positive BinaxNOW® UAT; 
notably, two patients had a positive UAT but negative sterile-site cultures (Table 1).  
 
Management 
Most patients (62%) received intravenous flucloxacillin and another penicillin. 
Following confirmation of pneumococcal infection, antimicrobial prescribing was amended 
in 23 (51%) patients, most commonly to benzylpenicillin, ceftriaxone or cefuroxime. The 
most utilised single-agent antimicrobial was a penicillin (Table 2). In the 42 surviving adults, 
mean duration of intravenous therapy was 16.4 ± 6.5 days, and total length of course was 
67.2 ± 14.1 days, with six adults receiving 90 day’s therapy. In total, 11 (24%) patients 
required treatment on intensive care (ITU) or a high-dependency unit (HDU), most frequently 
for ventilatory support necessitated by second-site pneumonia; all patients with concomitant 
meningitis required ITU/HDU care.  
Arthroscopic drainage was performed in 35 patients, and eight others underwent open 
incision and drainage. Three patients requiring open surgery had polyarticular infection and 
the affected joints included the knee (n=6), ankle (n=2) and shoulder (n=3). 
 
S. pneumoniae strains and outcomes 
Serotype data were available for 39 patients (87%). The most commonly isolated 
serotype was 12F (n=9), followed by 22F (n=4) and 3 (n=4). The proportion of cases due to 
 
 
PCV13 serotypes increased after PCV7 implementation in 2006, plateaued after PCV13 
implementation in 2010 before declining in recent years. During the last 6 study years (2013-
2018), the majority of cases (70%) were due to serotypes included in PPV23 only with eight 
cases due to non-vaccine serotypes (Figure 2).   
Of the 11 cases due to PCV13 serotype (Table 3) none required HDU/ITU care. These 
patients survived hospital admission: three died within one year, five survivors had reduced 
ROM, and four required increased care after hospital discharge.  
Serotypes in PPV23 only were responsible for 19 cases:  concomitant infection at 
another site was more frequent in this group compared to those with PCV13 serotype disease 
(P<0.05). Fourteen had pneumonia and all cases of septic arthritis associated with meningitis 
were attributable to serotypes 12F and 22F. Seven required ITU/HDU care; notably, this 
group accounted for 64% of patients requiring HDU/ITU care. Inpatient CFR but not 1-year 
CFR was higher compared to those with PCV13 disease (P<0.05).  
Non-vaccine serotypes were responsible for 11 cases, and none died of septic arthritis. 
Seven survived over a year. 
 
Discussion 
We have described one of the largest cohorts of patients with pneumococcal septic 
arthritis occurring over 13 years in South West England. This is the first report describing 
epidemiological trends of adult pneumococcal septic arthritis, including clinical 
characteristics and patient outcomes, following paediatric PCV implementation in the UK 
(PCV7 and PCV13). Septic arthritis accounted for 1.3% of IPD cases and many patients were 
elderly and/or had underlying comorbidities. A high proportion of patients had pneumococcal 
 
 
infection at a second site, mainly pneumonia, with three cases of meningitis. There was a 
trend towards increasing incidence of pneumococcal septic arthritis after polysaccharide 
conjugate vaccination (PCV7) introduction. Consistent with this observation was an increase 
followed by a decrease in pneumococcal septic arthritis cases caused by the additional 
PCV13 serotypes not included in PCV7. Pneumococcal septic arthritis was associated with an 
in-hospital case fatality rate of 6.7% and 31% died within 12 months, demonstrating similar 
fatality rates to hip fractures [21].  
 
Disease 
Prior to the UK routine implementation of PCVs, septic arthritis represented 2.4% of 
IPD cases compared to 1.3% since PCV7 introduction [7]. This is consistent with 1.5% 
reported in recent studies from France and Canada [22,23]. Patients with pneumococcal 
septic arthritis in our cohort were typically elderly, with two or more risk factors pre-
disposing them to IPD. A case series and literature review of 108 adults reported mean age 59 
years [8], while 80% cases diagnosed during 1985-1998 in Nottingham, UK, were aged >60 
years [7] consistent with more recent studies [22,24]. Additionally, 79-92% patients with 
pneumococcal septic arthritis in reported studies had recognised risk factors. In a case series 
of 51 patients from Alberta, Canada, an inability to walk independently, male gender and 
underlying joint disease were identified as important risk factors for pneumococcal septic 
arthritis [23]. Uniquely, one patient in our cohort was pregnant when she developed 
pneumococcal septic arthritis; this has not been reported previously in the literature.  
In keeping with published studies, the knee was the most affected joint: this included 
prosthetic joint infection, which contributed 11% to our cohort of cases. This prevalence is at 
the lower end of the range reported (11-31%) [7,8,22,24] and may arise from factors 
 
 
unaccounted for by this study, including the number of prosthetic implants performed in our 
area. S. pneumoniae should be considered as a potential cause of septic arthritis in elderly 
patients presenting with swollen joints, especially knee and shoulder joints. 
Over half (58%) our cohort had concomitant pneumococcal infections at another site, 
mainly pneumonia, at the higher end of the 28-56% range reported by other studies [7,8,24]. 
Septic arthritis was considered the primary focus of infection in almost all the patients in this 
cohort, with joint pain or loss of function being reported as the main presenting symptom’s 
the second site infection was detected on further clinical examination and investigation. This 
highlights the importance of thorough clinical examination – especially of the joints – in 
elderly patients presenting with features of pneumonia, which was frequently the reason for 
such patients to require HDU/ITU care. 
 
Deaths and outcomes 
In keeping with previous studies and with septic arthritis overall, the in-hospital CFR 
for pneumococcal septic arthritis in our cohort was low (6.7%). The clinical team noted that 
all patients who died were frail. Two died within 72 hours of admission; all developed 
respiratory failure secondary to severe bilateral pneumonia. However, by one year after 
hospitalisation, 31% patients had died, including 80% of patients aged ≥80 years. Further 
studies are needed to identify potentially modifiable factors to improve long-term outcomes 
of pneumococcal septic arthritis in the elderly.   
Of those who survived, 22% patients required discharge to a rehabilitation or 
specialist treatment unit. Additionally, 42% (n=13) had long-term reduced ROM, 
substantially higher than the 21-36% reported in the literature [7,8,22]. All patients with 
 
 
complicated pneumococcal infection (empyema, meningitis or mycotic aneurysm) had long-
term reduced ROM of the affected joint.   
The increased care requirement at discharge was particularly common for older 
patients who frequently required additional mobility aids and care. Knowledge of functional 
loss and additional care need is important for setting the expectations of patients and their 
families in respect to future care requirement. Furthermore, the arrangement of care packages 
and equipment often results in delays in hospital discharge [25], increasing the risk of 
hospital-acquired infection and decline in mobility and loss of independence for patients, as 
5% of muscle strength is lost with each day in hospital [26-28].  
 
Implications 
The epidemiology of pneumococcal serotypes causing septic arthritis has shifted over 
the past decade due to the implementation of two pneumococcal immunisation programmes: 
PCV7 in 2006 and PCV13 in 2010. Others have reported increasing incidence of 
pneumococcal septic arthritis following PCV13 introduction, with 40% of cases attributable 
to non-PCV13 serotypes [22]. We found differences in disease presentation between the 
different vaccine serotype groups, particularly septic arthritis due to PPV23nonPCV13 and 
non-vaccine serotypes, which appeared to be associated with more severe disease, including a 
higher prevalence of concomitant pneumococcal infection at another site, increased 
ITU/HDU admission, and higher inpatient CFR in comparison to PCV13 serotype adult 
septic arthritis. Numbers of cases, however, were small and, therefore, additional studies are 
required to confirm this finding, especially given that currently nearly all cases are due to 




Strengths and Limitations 
This study captured patients with proven pneumococcal disease in a large 
geographical area with a population of nearly a million adults, encompassing 3 large hospitals 
with 100000 unplanned admissions and 270000 emergency department attendances by adult 
patients annually. We studied pneumococcal disease over 13 years, spanning the period 
before and after PCV13 implementation, allowing us to assess disease trends over time. 
Furthermore, linking our cases with the PHE national reference laboratory provided serotype 
information for almost all cases. A major strength is that epidemiological data were supported 
with detailed clinical information for individual patients, including short- and long-term 
outcomes.  
This is a retrospective observational study; therefore, only data documented in clinical 
records could be collected. Despite the large IPD cohort, pneumococcal septic arthritis was 
diagnosed in only a small proportion of cases. Additionally, our regional findings may not 
apply to other populations. Patients were managed according to clinicians’ discretion, which 
may have influenced the investigation and management of individual patients, including 
requirement for HDU/ITU care, surgical management and discharge preferences. We 
included patients who tested positive for pneumococcus using the BinaxNOW® urinary 
antigen test, with a known sensitivity of 65% and prolonged positive test result after exposure 
to pneumococcus [29], although only two patients were solely diagnosed in this way. Finally, 
different methodologies were used during the study period to identify pneumococcal 
serotypes; whole genomic sequencing was not routinely used by PHE until October 2017, and 




In conclusion, pneumococcal septic arthritis is responsible for a small proportion of 
IPD cases and mainly affected the elderly, who often have multiple underlying comorbidities. 
While inpatient CFR was low, almost a third of patients died within one year. The increasing 
rate and severity of pneumococcal septic arthritis, currently mainly due to non-PCV13 
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Table 1: Characteristics of patients with S. pneumoniae septic arthritis between 2006 and 
2018 
Characteristic or finding All Patients  n (%) 
Age (years)  
    16-29 1 (2.2) 
    30-49 6 (13.3) 
    50-64 9 (20.0) 
    65-79 19 (42.2) 
    >80 10 (22.2) 
Gender  
Male 20 (44.4) 
Female 25 (55.6) 
Joint(s) involved  
    Hip 1 (2.2) 
    Knee 23 (51.1) 
    Ankle 6 (13.3) 
    Shoulder 11 (24.4) 
    Elbow 5 (11.1) 
    Wrist 5 (11.1) 
    Toe 2 (4.4) 
Prosthetic joint 5 (11.1) 
Monoarticular 37 (82.2) 
Polyarticular 8 (17.8) 
Other Infection Sites  
Preceding URTI 14 (31.1) 
Concomitant infection  30 (66.6) 
         Pneumonia 26 (57.8) 
         Meningitis 3 (6.7) 
         Other 1 (2.2) 
Risk Factors  
Recent blunt trauma to joint 16 (35.6) 
Underlying disease/risk factors  43 (95.6) 
 
 
Clinical presentation  
   Red, hot, swollen joint   43 (95.6) 
   Temperature ≥38°C 35 (77.8) 
   Tachycardia (heart rate ≥100bpm) 20 (44.4) 
   Hypotension † 6 (13.3) 
   Confusion (AMTS ≤7) 7 (15.6) 
Biochemistry Investigations  median (IQR) 
- Sodium (mmol/L) 135 (133-141) 
- Creatinine (μmol/L) 111 (78-134) 
- Urea (mmol/L) 8.1 (5.3-10.7) 
- eGFR (mL/min/1.73m
2
) 57 (38-70) 
- C-reactive protein (mg/L) 213 (126-307) 
- Albumin (g/L) 30.0 (27.0-32.0) 
Haematology Investigations  median (IQR) 
- WBC (×10
9
/L) 15.0 (12.2-20.1) 
- Neutrophil (×10
9
/L) 13.1 (10.2-16.9) 
- Lymphocyte (×10
9
/L) 1.3 (0.9-2.1) 
Microbiological diagnosis  n/total n (%) 
- Blood culture positive 28/45 (62.2) 
- UAT positive  8/45 (17.8) 
- Fluid culture positive only 13/45 (28.9) 
Positive joint fluid S. pneumoniae results  n/total n (%) 
 - Gram stain 37/45 (82.2) 
 - Culture 43/45 (95.6) 






AMTS, abbreviated mental test score; DBP, diastolic blood pressure; eGRF, estimated 
Glomerular Filtration Rate; SBP, systolic blood pressure; UAT, urinary antigen test; URTI, 
upper respiratory tract infection; WBC, white blood cell 





/L and lymphocytes 1.25×10
9
/L. 
† Hypotension was defined as SBP<100mmHg or DBP ≤60mmHg 
 
Table 2: Treatment and outcomes of S. pneumoniae septic arthritis 
Treatment or Outcome Cohort patients 
Antibiotic agents  
Penicillin 31/45 (68.9) 
  - alone 13/45 (28.9) 
  - in combination * 18/45 (40.0) 
Cephalosporin 12/45 (26.7) 
Fluoroquinolone 2/45 (4.4) 
Antibiotic treatment  
Single antibiotic class 28/45 (62.2) 
Multiple antibiotic classes 17/45 (37.8) 
Intravenous   
 
 
  - initial mode of administration 44/45 (97.8) 
  - unable to rationalise to oral 5/45 (11.1) 
Days until rationalisation – average ± SD 16.4 ± 6.5 
Length of antibiotic course – average ± SD 67.2 ± 14.1 
Surgical Management & 12 month outcomes  
Arthroscopic drainage 35/45 (77.8) 
   - Reduced ROM 15/35 
   - Cured 12/35 
   - Unknown joint function 8/35 
Incision and drainage 8/45 (17.8) 
   - Reduced ROM 2/8 
   - Cured 3/8 
   - Unknown joint function 3/8 
Complications  
ITU/HDU care** 11/45 (24.4) 
  - I&V 10/45 (22.2) 
  - Inotropic support 8/45 (17.8) 
Acute renal failure 9/45 (20.0) 
Liver dysfunction 4/45 (8.9) 
Admission   
Hospital length of stay – average (± SD) 24.9 ± 14.2 
Discharge destination  
  - Home 25/42 (59.5) 
  - Rehab/specialist centre 10/42 (23.8) 
  - Increased care requirement† 20/42 (47.6) 
Case fatality rate  
Inpatient  3/45 (6.7) 
- Monoarticular infection 1/45 (2.2) 
- Polyarticular infection 2/45 (4.4) 
1-year mortality 14/45 (31.1) 
HDU, high dependency unit; I&V, intubation and ventilation; ITU, intensive therapy unit; 
ROM, range of movement 
* Penicillin class antibiotic (including Benzylpenicillin, amoxicillin, co-amoxiclav, 
flucloxacillin) was given in combination with an aminoglycoside (n=1), cephalosporin (n=1), 
glycopeptide (n=14), macrolide (n=1), and nitroimidazole and aminoglycoside (n=1).  
** ITU/HDU care in addition to any requirement in the post-operative recovery period 
† Increased care requirement includes increasing packages of care or other support for 
patients discharged home, discharge to new care facility from patient’s home or increasing 
care facility requirement (eg nursing home from assisted living) 
 



















Male gender – n (%) 5 (45.5) 8 (42.1) 5 (45.5) 2 (50.0) 20 (44.4) 
Age (y) – median (IQR) 66 (59-
76) 








Smoker – n (%) 3 (27.3) 5 (26.3) 4 (36.4) 2 (50.0) 14 (31.1) 
Joint(s) involved – n 
(%) 
     
    Knee 6 (54.5) 9 (47.4) 5 (45.5) 3 (75.0) 23 (51.1) 
    Ankle 2 (18.2) 2 (10.5) 2 (18.2) 0 (0.0) 6 (13.3) 
    Shoulder 2 (18.2) 4 (28.6) 3 (27.2) 2 (50.0) 11 (24.4) 
    Elbow 1 (9.1) 2 (10.5) 1 (9.1) 1 (20.0) 5 (11.1) 
    Wrist 1 (9.1) 2 (14.3) 1 (9.1) 1 (20.0) 5 (11.1) 
Prosthetic joint 1 (9.1) 2 (10.5) 1 (9.1) 0 (0.0) 5 (11.1) 
Monoarticular 9 (81.8) 15 (78.7) 10 (90.9) 3 (75.0) 37 (82.2) 
Polyarticular 2 (18.2) 4 (21.1) 1 (9.1) 1 (25.0) 8 (17.8) 
Second Site Infection      
Second site infection  4 (36.6) 16 (84.2) * 7 (63.3) * 2 (50.0) 30 (66.6) 
         Pneumonia 4 (36.6) 14 (73.7) * 7 (63.3) * 2 (50.0) 26 (57.8) 
         Meningitis 0 (0.0) 3 (15.8) 0 (0.0) 0 (0.0) 3 (6.7) 
         Other 0 (0.0) 1 (5.3) 0 (0.0)  0 (0.0) 1 (2.2) 
Complications – n (%)      
ITU/HDU care** 0 (0.0) 7 (36.8) * 2 (18.2) 2 (50.0)  11 (24.4) 
  - I&V 0 (0.0) 6 (54.5) * 2 (18.2)  2 (50.0)  10 (22.2) 
  - Ionotropic support 0 (0.0) 4 (21.1) * 2 (18.2) 2 (50.0)  8 (17.8) 
Acute renal failure 3 (27.3) 4 (21.1) 0 (0.0) 2 (50.0) 9 (20.0) 
Admission – n (%)      
Hospital length of stay 
– average ± SD 
25.0 ± 
10.9 






Discharge destination      
 - Home 6 (54.5) 10 (52.6) 6 (54.5) 3 (75.0) 25 (55.6) 
 - Rehab/specialist 
centre 
3 (27.3) 3 (21.4) 2 (18.2) 2 (50.0) 10 (22.2) 
 - Increased care need 4 (36.6) 8 (42.1) 6 (54.5) 2 (50.0) 20 (44.4) 
Joint Function – n 
(%) 
     
Reduced ROM 5/8 (62.5) 6/16 (37.5) 3/8 (37.5) 1/3 (33.3) 15/35 
(42.9) 
Cured 3/8 (37.5) 4/16 (25.0) 4/8 (50.0) 1/3 (33.3) 12/35 
(34.3) 
Case fatality rates – n 
(%) 
     
Inpatient  0 (0.0) 3 (21.4) * 0 (0.0) 0 (0.0) 3 (6.7) 
1-year mortality 3 (27.3) 5 (26.3) 4 (36.4) 2 (50.0) 14 (31.1) 
HDU, High dependency unit; I&V, intubation and ventilation; ITU, intensive therapy unit; 
ROM, range of movement 
* P<0.01 Chi-squared test compared to PCV13 serotype disease. 
** ITU/HDU care in addition to any requirement in the post-operative recovery period 
PCV13 disease comprised of serotypes: 1 (n=2), 3 (n=4), 7F (n=3) and 19A (n=2); 
PPV23nonPCV13 disease comprised serotypes: 8 (n=2), 10A (n=3), 12F (n=9), 22F (n=4), 
33F (n=1); Non-vaccine serotypes included: 15A (n=2), 23A (n=2), 23B (n=2), 24F (n=2), 






Figure 1: Adult hospital admissions attributable to Streptococcus pneumoniae  
Rate of disease for hospitalisations due to (A) all pneumococcal disease and (B) septic 
arthritis per 100,000 adults. Error bars represent 95% CI. The dashed lines in Figure 1A show 
the introduction of PCV7 and PCV13.  
Disease incidence was calculated using adult population data from the Office of National 
Statistics (Supplementary data 1). 
 
Figure 2: Pneumococcal septic arthritis by vaccine group 
 
 
Figure 2A Cases of pneumococcal septic arthritis by vaccine group. White represents disease 
from serotypes contained within PCV13, black represents disease from PPV23nonPCV13 
serotypes and dashed lines represents disease from serotypes not contained in current 
pneumococcal vaccines.  
Figure 2B The number of cases attributable to individual serotypes, by vaccine type*, are 
listed within the table. 
* Serotypes included in both PCV13 and PPV23 are 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 
19A, and 23F. Additional serotypes in PPV23 are 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 






included serotype 4, 6B, 9V, 14, 18C, 19F and 23F which are also included in both PCV13 
and PPV23. 
 
Supplementary Table 1:  Annual Population and Hospital Admissions 
Population size within the Bristol, North Somerset and South Gloucestershire CCG and Bath 
& NE Somerset CCG as based on data obtained from the Office for National Statistics 
(ONS).  
Number of adult patients seen are listed as a combined total for all 3 NHS Trusts, from data 
provided by NHS Digital. Data for patients seen in Emergency Departments is derived from 
Hospital Accident and Emergency Activity. Data for admissions is collated from Monthly 
Hospital Episode Statistics for Admitted Patient Care, Outpatient and Accident and 
Emergency data 
























































































































































































































             







































Supplementary Table 2: Serotypes contained within each pneumococcal vaccination. 
Vaccination  Serotypes 
Pneumococcal polysaccharide 
vaccine, 23 valent  
(PPV-23, PneumoVax®) 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19F, 19A, 20, 22F, 23F, 33F. 
Pneumococcal conjugate 
vaccine, 7-valent (PCV-7, 
Prevenar®) 
4, 6B, 9V, 14, 18C, 19F and 23F 
Pneumococcal conjugate 
vaccine, 13-valent (PCV-13, 
Prevenar13®) 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 18C, and 23F 
 
 
Supplementary Data: NHS Trusts  
There are three hospitals in the Bristol and Bath area: The Bristol Royal Infirmary 
(University Hospitals Bristol NHS Foundation Trust), Southmead Hospital (North Bristol 
NHS Trust), and The Royal United Hospital in Bath. These hospitals are summarised in the 
table beneath:  
Summary of Hospital and Services Provided: 
 
Bristol Royal Infirmary Southmead Hospital  
Royal United 
Hospital 
Location Central Bristol North Bristol Bath 
 
 
Hospital Capacity (beds) 
1
   
Total 821 929 759 
Medical 440 538 423 
Surgical 178 274 117 
Critical Care 
(ICU/HDU) 
39 44 13 
Specialist Services    
Specialist Services  Cystic Fibrosis Neurosciences Rheumatology 
(adult) Cardio-thoracic Orthopaedic Centre  
 Haem & Oncology Plastics/Reconstruction  
 Ophthalmology Major Trauma  
 Ear, Nose & Throat 
Surgery 
Renal & Transplant  
 Oral & Maxillofacial 
Surgery 
Urology  
 Dental Services Vascular Services  
 Sleep & ventilation Pleural Medicine  
 
1 
Data extracted from NHS England: SDCS data collection- KH03, available at 
https://www.england.nhs.uk/statistics/statistical-work-areas/bed-availability-and-
occupancy/bed-data-overnight/ 
 
